Stability of Novel Siderophore Cephalosporin S-649266 against Clinically Relevant Carbapenemases

被引：151

作者：

Ito-Horiyama, Tsukasa ^{[1
]}

Ishii, Yoshikazu ^{[2
]}

Ito, Akinobu ^{[1
]}

Sato, Takafumi ^{[1
]}

Nakamura, Rio ^{[1
]}

Fukuhara, Norio ^{[3
]}

Tsuji, Masakatsu ^{[1
]}

Yamano, Yoshinori ^{[1
]}

Yamaguchi, Keizo ^{[2
]}

Tateda, Kazuhiro ^{[2
]}

机构：

[1] Shionogi & Co Ltd, Discovery Res Lab Core Therapeut Areas, Osaka, Japan

[2] Toho Univ, Sch Med, Tokyo, Japan

[3] Shionogi & Co Ltd, Global Innovat Off, Osaka, Japan

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2016年 / 60卷 / 07期

关键词：

D O I：

10.1128/AAC.03098-15

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

To better understand the antibacterial activity of S-649266 against carbapenemase producers, its stability against clinically relevant carbapenemases was investigated. The catalytic efficiencies (k(cat)/K-m) of IMP-1, VIM-2, and L1 for S-649266 were 0.0048, 0.0050, and 0.024 mu M-1 s(-1), respectively, which were more than 260-fold lower than that for meropenem. Only slight hydrolysis of S-649266 against KPC-3 was observed. NDM-1 hydrolyzed meropenem 3-fold faster than S-649266 at 200 mu M.

引用

页码：4384 / 4386

页数：3

共 50 条

[1] In Vitro Antimicrobial Activity of a Siderophore Cephalosporin, S-649266, against Enterobacteriaceae Clinical Isolates, Including Carbapenem-Resistant Strains
Kohira, Naoki
West, Joshua
Ito, Akinobu
Ito-Horiyama, Tsukasa
Nakamura, Rio
Sato, Takafumi
Rittenhouse, Stephen
Tsuji, Masakatsu
Yamano, Yoshinori
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2016, 60 (02) : 729 - 734
[2] ARGONAUT-I: Activity of Cefiderocol (S-649266), a Siderophore Cephalosporin, against Gram-Negative Bacteria, Including Carbapenem-Resistant Nonfermenters and Enterobacteriaceae with Defined Extended-Spectrum β-Lactamases and Carbapenemases
Jacobs, Michael R.
Abdelhamed, Ayman M.
Good, Caryn E.
Rhoads, Daniel D.
Hujer, Kristine M.
Hujer, Andrea M.
Domitrovic, T. Nicholas
Rudin, Susan D.
Richter, Sandra S.
van Duin, David
Kreiswirth, Barry N.
Greco, Chris
Fouts, Derrick E.
Bonomo, Robert A.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2019, 63 (01)
[3] Metabolism, Excretion, and Pharmacokinetics of [14C]-Cefiderocol (S-649266), a Siderophore Cephalosporin, in Healthy Subjects Following Intravenous Administration
Miyazaki, Shiro
Katsube, Takayuki
Shen, Helen
Tomek, Charles
Narukawa, Yukitoshi
JOURNAL OF CLINICAL PHARMACOLOGY, 2019, 59 (07): : 958 - 967
[4] In vitro antimicrobial activity of S-649266, a catechol-substituted siderophore cephalosporin, when tested against non-fermenting Gram-negative bacteria
Ito, Akinobu
Kohira, Naoki
Bouchillon, Samuel K.
West, Joshua
Rittenhouse, Stephen
Sader, Helio S.
Rhomberg, Paul R.
Jones, Ronald N.
Yoshizawa, Hidenori
Nakamura, Rio
Tsuji, Masakatsu
Yamano, Yoshinori
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2016, 71 (03) : 670 - 677
[5] Cefiderocol (S-649266), A new siderophore cephalosporin exhibiting potent activities against Pseudomonas aeruginosa and other gram-negative pathogens including multi-drug resistant bacteria: Structure activity relationship
Aoki, Toshiaki
Yoshizawa, Hidenori
Yamawaki, Kenji
Yokoo, Katsuki
Sato, Jun
Hisakawa, Shinya
Hasegawa, Yasushi
Kusano, Hiroki
Sano, Masayuki
Sugimoto, Hideki
Nishitani, Yasuhiro
Sato, Takafumi
Tsuji, Masakatsu
Nakamura, Rio
Nishikawa, Toru
Yamano, Yoshinori
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2018, 155 : 847 - 868
[6] Cefiderocol (S-649266): A new siderophore cephalosporin exhibiting potent activities against Pseudomonas aeruginosa and other gram negative-pathogens including multi-drug resistant bacteria: Structure activity relationship
Aoki, Toshiaki
Yoshizawa, Hidenori
Yamawaki, Kenji
Yokoo, Katsuki
Sato, Jun
Hisakawa, Shinya
Hasegawa, Yasushi
Kusano, Hiroki
Sano, Masayuki
Sugimoto, Hideki
Nishitani, Yasuhiro
Yamano, Yoshinori
Sato, Takafumi
Tsuji, Masakatsu
Nakamura, Rio
Nishikawa, Toru
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2017, 254
[7] Activity of cefiderocol (S-649266) against carbapenem-resistant Gram-negative bacteria collected from inpatients in Greek hospitals
Falagas, Matthew E.
Skalidis, Tilemachos
Vardakas, Konstantinos Z.
Legakis, Nicholas J.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2017, 72 (06) : 1704 - 1708
[8] Efficacy of Humanized Exposures of Cefiderocol (S-649266) against a Diverse Population of Gram-Negative Bacteria in a Murine Thigh Infection Model
Monogue, Marguerite L.
Tsuji, Masakatsu
Yamano, Yoshinori
Echols, Roger
Nicolau, David P.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2017, 61 (11)
[9] In Vitro Antibacterial Properties of Cefiderocol, a Novel Siderophore Cephalosporin, against Gram-Negative Bacteria
Ito, Akinobu
Sato, Takafumi
Ota, Merime
Takemura, Miki
Nishikawa, Toru
Toba, Shinsuke
Kohira, Naoki
Miyagawa, Satoshi
Ishibashi, Naoki
Matsumoto, Shuhei
Nakamura, Rio
Tsuji, Masakatsu
Yamano, Yoshinori
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2018, 62 (01)
[10] Cefiderocol: A Novel Siderophore Cephalosporin against Multidrug-Resistant Gram-Negative Pathogens
Abdul-Mutakabbir, Jacinda C.
Alosaimy, Sara
Morrisette, Taylor
Kebriaei, Razieh
Rybak, Michael J.
PHARMACOTHERAPY, 2020, 40 (12): : 1228 - 1247

← 1 2 3 4 5 →